Skip to main content
Premium Trial:

Request an Annual Quote

Genalice Teams up with Intel to Develop Products for the Sequencing Market


NEW YORK (GenomeWeb) – Dutch software company Genalice said this week that it has signed a product development partnership with Intel.

Under the terms of the agreement, Intel will be the main hardware supplier for Genalice. The partners will also work on optimizing the Genalice Map software to run on Intel Xeon Processors, the company said. Based on data from internal benchmarks, Genalice's software currently takes 24 hours each to map short reads from 42 human genomes and 42 tomato genomes when it's run on an Intel Xeon ES server. Moving forward, both companies will work on improving on these early results, according to Jos Lunenberg, Genalice's chief business officer.

Last week, Genalice announced that it had received a multimillion dollar capital investment from Redbrae, a consortium of US and UK-based private equity investors, to support product development and distribution. The company has not disclosed the exact amount of the investment.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.